Skip to main content
OpenTrials
Completed

NCT Number: NCT04503603

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

The purpose of this study to evaluate the safety, tolerability and pharmacokinetics (PK) of lanadelumab administered by Intravenous (IV) infusion in healthy adult volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

19 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Celerion

Lincoln, Nebraska, 68502, United States

About this study

A Randomized, Double-blind, Placebo-Controlled, Repeat-dose, Single-center Phase 1a Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Subjects

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, adult, male or female, 19-55 years of age, inclusive, at screening.
  • Continuous non-smoker who has not used nicotine-containing products for at least 30 days prior to the first dosing and throughout the study, based on participant self-reporting.
  • Body mass index (BMI) greater than or equal to (>=) 18.0 and less than or equal to (<=) 32.0 kilogram per square meter (kg/m^2) at screening.
  • Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), per the investigator.
  • Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential.
  • Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol.

Exclusion criteria

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease per the investigator.
  • History of any illness that might confound the results of the study or poses an additional risk to the participant by their participation in the study, per the investigator.
  • History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing per the investigator.
  • History or presence of hypersensitivity or idiosyncratic reaction to the study drug(s) or related compounds.
  • History or presence of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gall bladder removal, or current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinically significant clinical or laboratory assessments per the investigator.
  • Female participants with a positive pregnancy test or lactating.
  • Positive urine drug or alcohol results at screening.
  • Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
  • Supine blood pressure is less than 90/40 millimetre of mercury (mmHg) or greater than 140/90 mmHg at screening.
  • Supine heart rate is lower than 40 beats per minute (bpm) or higher than 99 bpm at screening.
  • Orthostatic vital sign results with a decrease in systolic greater than (>) 20 mmHg or decrease in diastolic > 10 mmHg and increase in pulse of > 20 beats per minute.
  • QTcF interval is > 450 milliseconds (msec) (males) or > 470 msec (females) or ECG findings are deemed abnormal with clinical significance at screening per the investigator.
  • Estimated creatinine clearance less than (<) 80 milliliters per minute (mL/min) at screening.
  • Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing and throughout the study. Medication listed as part of acceptable birth control methods will be allowed. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first study drug administration. After randomization/dosing, a nonsteroidal anti-inflammatory drug may be administered at the discretion of the investigator. Hormone replacement therapy will also be allowed if the participant has been on the same stable dose for the immediate 3 months prior to first study drug administration.
  • Has been on a diet incompatible with the on-study diet, per the investigator, within the 30 days prior to the first dosing and throughout the study.
  • Donation of blood or significant blood loss within 56 days prior to the first dosing.
  • Plasma donation within 7 days prior to the first dosing.
  • Participation in another clinical study within 30 days or 5 half-lives prior to the first dosing. The 30-day window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study

Treatment and study plan

Lanadelumab

Drug

Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.

Other names: TAK-743

Placebo

Other

Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.

Primary outcomes

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

    Time frame: From the first dose of study treatment up to the end of study (Day 112)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who has signed informed consent to participate in a study that did not necessarily have a causal relationship with the treatment. TEAEs were events that occurred on or after the date and time of administration of the first dose of study medication. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs were reported.

  2. Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

    Time frame: From the first dose of study treatment up to the end of study (Day 112)

    Clinical laboratory assessment included hematology, clinical chemistry, coagulation, and urinalysis. Any changes in clinical laboratory results that were deemed clinically significant were judged by the investigator. The number of participants with clinically significant change from baseline in laboratory values were reported.

  3. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: From the first dose of study treatment up to the end of study (Day 112)

    Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature (oral). Any changes in vital signs that were deemed clinically significant were judged by the investigator. The number of participants with clinically significant change from baseline in vital signs were reported.

  4. Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings

    Time frame: From the first dose of study treatment up to the end of study (Day 112)

    12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. Any changes in ECG parameters that were deemed clinically significant were judged by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.

  5. AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration for Lanadelumab

    Time frame: Pre-dose (Day 1) up to 2664 hours post-dose

    AUC0-last for lanadelumab was reported.

  6. AUC0-inf: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity for Lanadelumab

    Time frame: Pre-dose (Day 1) up to 2664 hours post-dose

    AUC0-inf for lanadelumab was reported.

  7. Cmax1: Maximum Observed Plasma Concentration Following the First IV Dose for Lanadelumab

    Time frame: Pre-dose (Day 1) up to 2664 hours post-dose

    Cmax1 following the first IV dose for lanadelumab was reported.

  8. Cmax2: Maximum Observed Plasma Concentration Following the Second IV Dose for Lanadelumab

    Time frame: Pre-dose (Day 4) up to 2592 hours post-dose

    Cmax2 following the second IV dose for lanadelumab was reported.

  9. Tmax1: Minimum Observed Time to Reach the First Cmax1 for Lanadelumab

    Time frame: Pre-dose (Day 1) up to 2664 hours post-dose

    Tmax1 following the first IV dose for lanadelumab was reported.

  10. Tmax2: Minimum Observed Time to Reach the Second Cmax2 for Lanadelumab

    Time frame: Pre-dose (Day 4) up to 2592 hours post-dose

    Tmax2 following the second IV dose for lanadelumab was reported.

  11. Terminal Half-Life (T1/2) of Lanadelumab in Plasma

    Time frame: Pre-dose (Day 1) up to 2664 hours post-dose

    T1/2 is defined as the time required for the concentration of the drug to reach half of its original value. T1/2 for lanadelumab was reported.

  12. Clearance (CL) of Lanadelumab in Plasma

    Time frame: Pre-dose (Day 1) up to 2664 hours post-dose

    Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL for lanadelumab was reported.

  13. Vss: Volume of Distribution at Steady State in Plasma for Lanadelumab

    Time frame: Pre-dose (Day 1) up to 2664 hours post-dose

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss for lanadelumab was reported.

  14. First Order Elimination Rate Constant Associated With the Terminal (Log-linear) Portion of the Curve (Lambda z) of Lanadelumab

    Time frame: Pre-dose (Day 1) up to 2664 hours post-dose

    Lambda z of Lanadelumab was reported.

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Collaborators

  • Takeda Development Center Americas, Inc.

Registry information

Official study title

A Randomized, Double-blind, Placebo-Controlled, Repeat-dose, Single-center Phase 1a Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Subjects

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Aug 7, 2020
Registry last updated
Mar 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.